Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05013957

Acronym

NEMESIs

Enrollment

Registered

2021-08-20

Start date

2022-01-01

Completion date

2024-12-30

Last updated

2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Tumors

Keywords

Methyloma

Brief summary

Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. The currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA represent a new, promising approach. The aim of this project is therefore to improve the diagnostic and prognostic evaluation of neuroendocrine neoplasms by means of methylation analysis of the tumor DNA. On the one hand, existing tumor samples from the biobank of Basel University Hospital are evaluated, on the other hand, patients who are undergoing an operation will be prospectively inquired

Interventions

DIAGNOSTIC_TESTMethylation analysis

Methylation analysis

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* neuroendocrine tumor

Exclusion criteria

* insufficient amount or quality of neuroendocrine tumor sample

Design outcomes

Primary

Measure	Time frame	Description
Methylation-based classification of NEN samples	3 years	NEN samples will be classified according to methylation analysis

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026